Public
Octapharma Locations
If this is your company, CONTACT US to activate Packbase™ software to build your portal.
Octapharma
Octapharma is a privately-owned global human proteins manufacturer headquartered in Lachen, Switzerland.
Octapharma is a privately-owned global human proteins manufacturer headquartered in Lachen, Switzerland. Since its establishment in 1983 the company has been dedicated to improving the lives of patients.
Octapharma’s commitment to patient care started right from the very beginning. We have a history of setting the benchmark for product and patient safety and were the first manufacturer to apply the solvent/detergent (S/D) viral inactivation process to production. We are committed to developing innovative products which help improve patient quality of life.
Coagulation disorders
Octapharma develops and manufactures high-purity coagulation factor concentrates for patients with bleeding disorders.
These plasma products are produced to the highest standards, using the latest technology, in state of the art manufacturing facilities to ensure the most advance solutions are available to patients globally.
Bleeding disorders
'Bleeding disorder' is a general term for a wide range of medical problems that lead to poor blood clotting and continuous bleeding, including:
Haemophilia A
Haemophilia B
von Willebrand disease (VWD)
In people with such disorders, clotting factors like Factor VIII, Factor IX or von Willebrand factor (VWF) are missing or don't work as they should. This causes these people to bleed for a longer time than those whose blood factor levels are normal. Early on-demand or prophylactic therapy that replaces the missing coagulation factor is able to effectively control or prevent acute bleeding in this group of patients.
Immune-Mediated Diseases and Deficiencies
Octapharma develops and manufactures high-purity human immunoglobulin products for treating immune-mediated diseases and deficiencies.
The immune system plays a key role in numerous conditions. In so-called immune deficiencies, the patient is prone to severe infections due to a lack of naturally occurring protective antibodies (immunoglobulins). Such patients need replacement of the missing immunoglobulins in order to protect them against infections and ensure they can lead a normal life.
Conditions where the immune system is out of balance are generally referred to as immune-mediated diseases, of which auto-immune diseases are a well-known subgroup. Such conditions may lead to various diseases, including bleeding disorders with a reduced number of blood platelets (immune thombocytopenic purpura (ITP)) and inflammatory neurologic conditions such as Guillain-Barré-Syndrome (GBS), chronic demyelinating polyradiculoneuropathy (CIDP) or multiple sclerosis (MS). Many other organ systems can also be a target of an immune-mediated disease.
Immunotherapy treats immune diseases and deficiencies by inducing, enhancing, or suppressing an immune response through immunomodulation or immunoglobulin replacement therapy.
Indications for Octapharma's immunotherapy products
Primary Immunodeficiency (PID)
Myeleoma and chronic lymphatic leukaemia (CLL) with severe secondary hypogrammaglobulinaemia
Immune thrombocytopenic purpura (ITP)
Kawasaki disease
Guillain Barre Syndrome (GBS)
Children with congenital AIDS and recurrent infections
Allogeneic bone marrow transplantation
